Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (68231)	4/13/1999 12:43:00 PM
From: taffard	Respond to of 119973

acel anybody notice this story on bussiness wire Tuesday April 13, 11:33 am Eastern Time Company Press Release ALFACELL Presents Promising Breast Cancer Data At AACR Conference Combination of ONCONASE and Doxorubicin Shows Survival Benefit in Mice BLOOMFIELD, N.J.--(BUSINESS WIRE)--April 13, 1999--ALFACELL Corporation (NASDAQ: ACEL - news) presented the results of in vivo studies conducted by the National Cancer Institute at the 90th Annual Meeting of the American Association for Cancer Research in Philadelphia, PA. In both flank and systemic nude mouse models, the combination regimen of ONCONASE and doxorubicin had a significantly greater effect than either drug alone demonstrating a synergism of this drug combination against human MDA-MB-231 breast cancer. In the flank model, tumor cells were injected subcutaneously and tumor volume was measured weekly from the beginning of treatment. In the systemic model, tumor cells were injected intravenously. Six to twelve mice per group were treated in both systems. Both drugs were given twice a week for three weeks. The combination regimen had a significantly greater effect on tumor growth inhibition than either agent alone in both animal models. The combination had a significantly greater effect on prolonging survival with the median survival time in days for the control group of 58, for ONCONASE of 72, for doxorubicin of 76 and for ONCONASE and doxorubicin of 187 days. Tumor-bearing mice treated with the combination therapy achieved a 222% increase in life span with 30% long-term survivors. The beneficial effect of this combination regimen on survival was also confirmed at a lower dose of doxorubicin. In vitro data was also presented in an abstract by Dr. Intae Lee of the University of PA showing ONCONASE as a potential radiation sensitizer. ALFACELL Corporation is a leader in the development of ribonucleases (RNases) for therapeutic applications. ONCONASE, an antitumor agent, is currently being investigated in Phase III clinical trials in patients with unresectable malignant mesothelioma. Onconase is being evaluated by scientists at the National Institutes of Health (NIH) for its preclinical anticancer activity in a variety of tumor systems. ALFACELL is located in Bloomfield, New Jersey, and the Company's common stock is traded on NASDAQ SmallCap under the symbol ''ACEL''. Contact: